UBS Group’s Marker Therapeutics MRKR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12K | Sell |
8,150
-24,219
| -75% | -$35.3K | ﹤0.01% | 8472 |
|
|
2026
Q1 | $42.1K | Sell |
32,369
-141,657
| -81% | -$225K | ﹤0.01% | 7485 |
|
|
2025
Q4 | $259K | Buy |
174,026
+168,232
| +2,904% | +$191K | ﹤0.01% | 6441 |
|
|
2025
Q3 | $5.17K | Buy |
5,794
+4,194
| +262% | +$5.18K | ﹤0.01% | 8892 |
|
|
2025
Q2 | $2.45K | Sell |
1,600
-12,711
| -89% | -$16.3K | ﹤0.01% | 9468 |
|
|
2025
Q1 | $17.6K | Buy |
+14,311
| New | +$26.2K | ﹤0.01% | 8313 |
|
|
2024
Q4 | – | Sell |
-19,104
| Closed | -$53.9K | – | 10230 |
|
|
2024
Q3 | $53.9K | Buy |
+19,104
| New | +$75.6K | ﹤0.01% | 6770 |
|
|
2024
Q2 | – | Sell |
-427
| Closed | -$1.84K | – | 9894 |
|
|
2024
Q1 | $1.84K | Buy |
+427
| New | +$1.86K | ﹤0.01% | 8037 |
|
|
2023
Q4 | – | Sell |
-93
| Closed | -$422 | – | 9685 |
|
|
2023
Q3 | $422 | Sell |
93
-1,414
| -94% | -$7.9K | ﹤0.01% | 8506 |
|
|
2023
Q2 | $4.67K | Sell |
1,507
-4,102
| -73% | -$7.13K | ﹤0.01% | 7508 |
|
|
2023
Q1 | $3.98K | Buy |
5,609
+5,234
| +1,396% | +$12.4K | ﹤0.01% | 8248 |
|
|
2022
Q4 | $1.01K | Sell |
375
-4,284
| -92% | -$14.8K | ﹤0.01% | 9995 |
|
|
2022
Q3 | $17K | Buy |
4,659
+4,301
| +1,201% | +$15.8K | ﹤0.01% | 7605 |
|
|
2022
Q2 | $1K | Sell |
358
-233
| -39% | -$775 | ﹤0.01% | 9908 |
|
|
2022
Q1 | $3K | Sell |
591
-484
| -45% | -$2.77K | ﹤0.01% | 9462 |
|
|
2021
Q4 | $10K | Buy |
+1,075
| New | +$14.3K | ﹤0.01% | 8789 |
|
|
2021
Q3 | – | Sell |
-873
| Closed | -$25K | – | 9869 |
|
|
2021
Q2 | $25K | Sell |
873
-847
| -49% | -$22.3K | ﹤0.01% | 7110 |
|
|
2021
Q1 | $39K | Buy |
1,720
+881
| +105% | +$20.2K | ﹤0.01% | 6787 |
|
|
2020
Q4 | $12K | Buy |
839
+390
| +87% | +$6.05K | ﹤0.01% | 7348 |
|
|
2020
Q3 | $7K | Sell |
449
-651
| -59% | -$11.9K | ﹤0.01% | 7127 |
|
|
2020
Q2 | $23K | Sell |
1,100
-478
| -30% | -$10.5K | ﹤0.01% | 6467 |
|
|
2020
Q1 | $30K | Sell |
1,578
-2,476
| -61% | -$63.1K | ﹤0.01% | 6208 |
|
|
2019
Q4 | $117K | Buy |
4,054
+1,720
| +74% | +$62.6K | ﹤0.01% | 5923 |
|
|
2019
Q3 | $119K | Sell |
2,334
-289
| -11% | -$17.1K | ﹤0.01% | 5658 |
|
|
2019
Q2 | $208K | Buy |
2,623
+838
| +47% | +$49.8K | ﹤0.01% | 4891 |
|
|
2019
Q1 | $118K | Buy |
1,785
+1,700
| +2,000% | +$99.2K | ﹤0.01% | 4950 |
|
|
2018
Q4 | $5K | Buy |
85
+38
| +81% | +$2.77K | ﹤0.01% | 7548 |
|
|
2018
Q3 | $4K | Sell |
47
-550
| -92% | -$47.2K | ﹤0.01% | 7577 |
|
|
2018
Q2 | $57K | Buy |
597
+317
| +113% | +$16.2K | ﹤0.01% | 5876 |
|
|
2018
Q1 | $9K | Buy |
280
+44
| +19% | +$1.55K | ﹤0.01% | 6940 |
|
|
2017
Q4 | $9K | Buy |
236
+30
| +15% | +$921 | ﹤0.01% | 7095 |
|
|
2017
Q3 | $6K | Buy |
206
+5
| +2% | +$158 | ﹤0.01% | 7151 |
|
|
2017
Q2 | $8K | Buy |
+201
| New | +$7.91K | ﹤0.01% | 6913 |
|
Other funds holding MRKR
BOCH
VCM
ACM
VFT
CIA
UBS Group's MRKR Position: Q2 2026 in Review
UBS Group reduced its Marker Therapeutics (MRKR) stake by 75% in Q2 2026, selling an estimated $35.3K and leaving 8,150 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #8472.
UBS Group first reported a position in MRKR in Q2 2017 and has held it in 33 quarters since. The position peaked at $259K in Q4 2025. 25 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.
- UBS Group held 8,150 shares of Marker Therapeutics worth $12K as of Q2 2026.
- UBS Group sold 24,219 Marker Therapeutics shares in Q2 2026, an estimated $35.3K.
- Marker Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8472 holding.
- UBS Group first reported a position in Marker Therapeutics in Q2 2017 and has held it in 33 quarters since.
- UBS Group's Marker Therapeutics position peaked at $259K in Q4 2025.
- 25 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.